8 results about "Drug responsiveness" patented technology

The invention discloses a humanized osteoporosis mouse model and a construction method thereof, and belongs to the technical field of biotechnology and animal models. The invention aims at the core defects of large species difference, insufficient humanization degree, low pathological simulation degree, unstable phenotype and the like of the existing osteoporosis model. The humanized osteoporosis mouse model is constructed through five core steps of experimental animal pretreatment, collagen-nano hydroxyapatite bionic scaffold preparation and cell pre-implantation, immune-bone metabolism double-derived system construction, progressive osteoporosis induction and model identification and verification. According to the method, double-person origination of immune and bone metabolism systems is realized for the first time, the colonization rate and survival time of human cells are greatly improved, the pathological process of clinical postmenopausal osteoporosis is accurately simulated, the phenotype of the model is stable and uniform, the reactivity matching degree with clinical drugs is high, and the method can be widely applied to research and development of anti-osteoporosis drugs and research of pathological mechanisms.

In a surface-enhanced Raman scattering-based method for testing drug reactivity of cerebrovascular cells, a SERS substrate is manufactured. A SERS substrate array including a plurality of the SERS substrates is manufactured. Cells are cultured on the SERS substrate array. A drug is administered to the cultured cells. A Raman signal is measured from the cells to which the drug is administered. An optimal drug is selected from among the administered drugs on the basis of the measured Raman signal.

The present invention features methods, devices, and kits for detecting gene expression in a patient with a cancer or determining responsive of a patient with a cancer to a treatment, such as treatment with 2X-121 or a pharmaceutically acceptable salt thereof. The invention further includes methods of treating a patient with a cancer by administering a treatment, e.g., treatment with 2X-121 or a pharmaceutically acceptable salt thereof, in particular when the patient is determined to be responsive to the treatment based on the expression of the biomarkers described herein.

The invention discloses a nucleic acid composition, an anti-allergic drug associated diagnosis detection kit and a micro-fluidic chip, and relates to the field of allergy detection. The nucleic acid composition disclosed by the invention realizes multi-target cooperative detection through three-section design: the histamine receptor aptamer specifically recognizes the histamine receptor and triggers the change of a stem-loop structure, and the leukotriene receptor response type DNA skeleton enhances the binding stability with the leukotriene receptor through a repetitive sequence; and the drug-triggered auxiliary chain promotes the formation of the complex by prolonging the tail of the poly (adenylic acid). The three components form a cascade reaction, the inflammatory mediator level and the drug responsiveness can be synchronously detected, the detection is more comprehensive than single target detection, and the structural parametric design ensures the suitability and repeatability.

The disclosure relates to a system comprising software that predicts responsiveness of healthy subjects or subjects at risk for or suffering from Alzheimer's Disease to certain disease modifying drugs. Embodiments of the disclosure include methods comprising analyzing images of the brain for depositions of amyloid-beta (Aβ) protein and tau protein, and correlating protein deposition levels to drug responsiveness.

The invention provides a construction method of a retinal vein occlusion animal model, and belongs to the technical field of medicines. The method comprises the following steps of: performing eyeball surface anesthesia on an anesthetized non-human primate animal, puncturing an eyeball after disinfection to establish two sclera tunnels, respectively inserting an illumination optical fiber and an intraocular laser optical fiber into the two sclera tunnels, then injecting a photosensitizer through limb vein, immediately performing laser photocoagulation on the retinal vein under illumination of the illumination optical fiber after injection, and performing laser photocoagulation on the retinal vein under the illumination of the illumination optical fiber. And obtaining the retinal vein occlusion animal model. According to the method, the retinal vein occlusion model can be successfully constructed, secondary macular edema and vascular recanalization are carried out for a long time and can be maintained for 4-5 weeks, the manifestation sign of retinal hemorrhage after retinal vein occlusion is close to that of human beings, and the method has clinical drug responsiveness, shows the clinical research value and has good application prospects. And a good research model is provided for research in the aspects of etiology, pathology and therapeutics.

The invention belongs to the technical field of tumor biology and organoids, and provides application of PARVA in promoting formation of tumor organoids. The PARVA comprises a PARVA protein or a PARVA coding gene; the application comprises application in preparation of a tumor organoid inducer, a tumor organoid culture kit and construction of a tumor organoid model. According to the invention, the formation efficiency and stability of the tumor organoid can be obviously improved, the difficulty in constructing the organoid with difficult-to-cultivate tumors such as lung cancer and bile duct cancer is solved, and a reliable model is provided for the fundamental research of the tumors; the constructed tumor organ model has a tissue structure, gene characteristics and drug responsiveness which are highly similar to in-vivo tumors, can be used for tumor generation mechanism research, antitumor drug high-throughput screening and clinical personalized treatment scheme evaluation, and has important scientific research value and clinical transformation significance.

The invention discloses a fluorescence quenching probe for targeting tumor cell apoptosis and application of the fluorescence quenching probe. The fluorescent quenching probe for targeting tumor cell apoptosis comprises a Caspase enzyme substrate specific recognition site Asp-Glu-Val-Asp, a fluorescent group, a quenching group and a tumor specific peptide fragment ligand P160. According to the invention, tumor drug response and immune infiltration and killing effect can be visually represented, and based on tumor cell endocytosis effect, the marking efficiency is significantly higher than that of a conventional probe. The method can be used for breast tumor drug response mechanism or toxicology research and anti-tumor immune polarization research. Compared with a traditional drug sensitive detection system, the tumor cell apoptosis can be monitored in real time, and the drug responsiveness can be detected in a shorter time; and the immune killing effect can be quantitatively evaluated by realizing targeted detection of tumor killing under a complex organ-like model. The probe is combined with a microwell plate technology, so that micro-scale, visual and quantitative research of drug sensitivity detection can be realized.